Areplivir®: the best launch 2021 in the retail segment according to IQVIA
Areplivir® manufactured by Promomed Group took the first place in the nomination "The best prescription drug in the retail segment in 2021" at IQVIA RX Awards.
For the fifth year in a row, the IQVIA Client Day event hosts the IQVIA RX Awards ceremony, at which the winners are announced, determined using the information from the Pharmatrend database (retail audit of drug sales from pharmacies).
On October 21, medicinal product Areplivir® developed and manufactured by Promomed Group was awarded the title "The best launch of a prescription drug in the retail segment in 2021" based on data from the Pharmatrend database (retail audit of drug sales from pharmacies).
"The victory in the IQVIA RX Awards with the direct anti-COVID antiviral drug Areplivir, which was developed and put into production in shortest time, was a deserved result of the efforts of the entire team. This is a sign of the quality of the product, recognition of its demand by patients, confirmation of effectiveness. This award is a great motivation to create new drugs that save lives," commented Maxim Smagin, General Director of Promomed.
In September 2020Promomed Group was one of the first companies in Russia to receive a permanent marketing authorization certificate for a drug against SARS-COV-2 and it made it possible to use the drug on an outpatient basis. Almost immediately, Areplivir® was included in the guidelines of the Ministry of Health of the Russian Federation for the treatment of COVID-19, and by order of the Government of the Russian Federation from 21.10.2020 it was included in the list of vital and essential medicines (VED).
